Therapeutic potential of selectively targeting the α2C -adrenoceptor in cognition, depression, and schizophrenia—New developments and future perspective

Frontiers in Psychiatry

Volumn 8, Issue AUG, 2017, Pages

  Uys, Madeleine Monique ^a   Shahid, Mohammed ^b   Harvey, Brian Herbert ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b Orion Corporation   (United Kingdom)

Author keywords

Alzheimer's disease; Cognition; Depression; ORM 10921; Schizophrenia; 2C antagonism

Indexed keywords

EID: 85028049031     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2017.00144     Document Type: Review

References (250)

1. Langer SZ. α2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci (2015) 36:196–202. doi:10.1016/j.tips.2015.02.006
2. 1 receptor signaling in the prefrontal cortex. Brain Res (2016) 1641:189–96. doi:10.1016/j.brainres.2015.11.024
3. Kalkman HO, Loetscher E. α2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol (2003) 462:33–40. doi:10.1016/ S0014-2999(03)01308-6
4. Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (2009) 23:65–73. doi:10.1177/0269881107082944
5. Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D. Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol (1993) 13:264–7. doi:10.1097/ 00004714-199308000-00006
6. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br J Psychiatry (1996) 168:571–9. doi:10.1192/bjp.168.5.571
7. Marcus MM, Wiker C, Franberg O, Konradsson-Geuken A, Langlois X, Jardemark K, et al. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol (2010) 13:891–903. doi:10.1017/S1461145709990794
8. Grossman F, Potter WZ, Brown EA, Maislin G. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord (1999) 56:237–43. doi:10.1016/S0165-0327(99)00041-5
9. Dhir A, Kulkarni SK. Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology (2007) 80:239–43. doi:10.1159/ 000104877
10. Rénéric JP, Bouvard M, Stinus L. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology (2001) 24:379–90. doi:10.1016/S0893-133X(00)00214-1
11. Coull JT, Sahakian BJ, Hodges JR. The α2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology (1996) 123:239–49. doi:10.1007/ BF02246578
12. Arnsten AFT. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry (2011) 69:e89–99. doi:10.1016/j.biopsych.2011.01.027
13. Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/ hyperactivity and related disorders. J Child Adolesc Psychopharmacol (2013) 23:308–19. doi:10.1089/cap.2013.0028
14. Hein L, Altman JD, Kobilka BK. Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission. Nature (1999) 402:181–4. doi:10.1038/46040
15. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adren-ergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol (2002) 283:R287–95. doi:10.1152/ajpregu.00123.2002
16. Scheinin M, Sallinen J, Haapalinna A. Evaluation of the α2C-adrenoceptor as a neuropsychiatric drug target: studies in transgenic mouse models. Life Sci (2001) 68:2277–85. doi:10.1016/S0024-3205(01)01016-5
17. Sallinen J, Höglund I, Engström M, Lehtimäki J, Virtanen R, Sirviö J, et al. Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302. Br J Pharmacol (2007) 150:391–402. doi:10.1038/sj.bjp.0707005
18. Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimäki J, et al. Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol (2013) 113:239–49. doi:10.1111/bcpt.12090
19. Sallinen J, Rouru J, Lehtimäki J, Marjamaeki P, Haaparanta-Solin M, Arponen E, et al. ORM-12741: receptor pharmacology of a novel alpha2cadrenergic receptor subtype selective antagonist with multi-therapeutic potential. Neuropsychopharmacology (2013) 38:S558–558.
20. Uys M, Shahid M, Sallinen J, Dreyer W, Cockeran M, Harvey BH. The alpha2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry (2016) 71:108–16. doi:10.1016/j.pnpbp.2016.07.002
21. Uys MM, Shahid M, Sallinen J, Harvey BH. The alpha2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders sensitive line rat. Behav Pharmacol (2017) 28:9–18. doi:10.1097/FBP.0000000000000261
22. Neumeister A, Drevets WC, Belfer I, Luckenbaugh DA, Henry S, Bonne O, et al. Effects of a α2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression. Neuropsychopharmacology (2006) 31:1750–6. doi:10.1038/sj.npp.1301010
23. Cho S-C, Kim J-W, Kim B-N, Hwang J-W, Shin M-S, Park M, et al. Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample. Neurosci Lett (2008) 446:108–11. doi:10.1016/j.neulet.2008.09.058
24. Rivero G, Martin-Guerrero I, de Prado E, Gabilondo AM, Callado LF, Garcia-Sevilla JA, et al. Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World J Biol Psychiatry (2016) 17:308–15. doi:10.3109/1562297 5.2016.1142608
25. Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, et al. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimers Dement (N Y) (2017) 3:1–9. doi:10.1016/j.trci.2016.11.004
26. Bücheler MM, Hadamek K, Hein L. Two α2-adrenergic receptor subtypes, α2A and α2C, inhibit transmitter release in the brain of gene-targeted mice. Neuroscience (2002) 109:819–26. doi:10.1016/S0306-4522(01)00531-0
27. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, et al. Distribution of α2-adrenergic receptor subtype gene expression in rat brain. Mol Brain Res (1994) 21:133–49. doi:10.1016/0169-328X(94)90386-7
28. Rosin DL, Talley EM, Lee A, Stornetta RL, Gaylinn BD, Guyenet PG, et al. Distribution of α(2C)-adrenergic receptor-like immunoreactivity in the rat central nervous system. JComp Neurol (1996) 372:135–65. doi:10.1002/ (SICI)1096-9861(19960812)372:1<135::AID-CNE9>3.3.CO;2-B
29. Bunemann M, Bucheler MM, Philipp M, Lohse MJ, Hein L. Activation and deactivation kinetics of alpha 2A- and alpha 2C-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents. J Biol Chem (2001) 276:47512–7. doi:10.1074/jbc.M108652200
30. Ordway GA. Effect of noradrenergic lesions on subtypes of α2-adrenoceptors in rat brain. J Neurochem (1995) 64:1118–26. doi:10.1046/j.1471-4159.1995.64031118.x
31. Esteban S, Lladó J, García-Sevilla JA. α2-Autoreceptors and α2-heteroreceptors modulating tyrosine and tryptophan hydroxylase activity in the rat brain in vivo: an investigation into the α2-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol (1996) 353:391–9.
32. Meana JJ, Callado LF, Pazos A, Grijalba B, Garcia-Sevilla JA. The subtype-se-lective alpha 2-adrenoceptor antagonists BRL 44408 and ARC 239 also recognize 5-HT1A receptors in the rat brain. Eur J Pharmacol (1996) 312:385–8. doi:10.1016/0014-2999(96)00598-5
33. Scheibner J, Trendelenburg AU, Hein L, Starke K. α 2-Adrenoceptors modulating neuronal serotonin release: a study in α2-adrenoceptor subtype-deficient mice. Br J Pharmacol (2001) 132:925–33. doi:10.1038/sj.bjp. 0703882
34. Björklund M, Sirviö J, Puoliväli J, Sallinen J, Jäkälä P, Scheinin M, et al. α(2C)-Adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape strategies. Mol Pharmacol (1998) 54:569–76.
35. Björklund M, Sirviö J, Riekkinen M, Sallinen J, Scheinin M, Riekkinen P Jr. Overexpression of alpha2c-adrenoceptors impairs water maze navigation. Neuroscience (1999) 95:481–7. doi:10.1016/S0306-4522(99)00428-5
36. Björklund M, Sirviö J, Sallinen J, Scheinin M, Kobilka BK, Riekkinen P Jr. Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns. Neuroscience (1999) 88:1187–98. doi:10.1016/ S0306-4522(98)00306-6
37. Björklund M, Siverina I, Heikkinen T, Tanila H, Sallinen J, Scheinin M, et al. Spatial working memory improvement by an α2-adrenoceptor agonist dexmedetomidine is not mediated through α2C-adrenoceptor. Prog Neuropsychopharmacology Biol Psychiatry (2001) 25:1539–54. doi:10.1016/ S0278-5846(01)00209-3
38. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther (2007) 113:523–36. doi:10.1016/j.pharmthera.2006.11.006
39. Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AFT. Mutation of the α2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci (2002) 22:8771–7.
40. Sallinen J, Haapalinna A, MacDonald E, Viitamaa T, Lähdesmäki J, Rybnikova E, et al. Genetic alteration of the α2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry (1999) 4:443–52. doi:10.1038/sj.mp.4000543
41. Schramm NL, McDonald MP, Limbird LE. The α2A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci (2001) 21:4875–82.
42. Zhang HT, Whisler LR, Huang Y, Xiang Y, O'Donnell JM. Postsynaptic α-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology (2009) 34:1067–77. doi:10.1038/npp.2008.184
43. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. Adrenergic α(2C)-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci (1998) 18:3035–42.
44. Lähdesmäki J, Sallinen J, MacDonald E, Scheinin M. Alpha2A-adrenoceptors are important modulators of the effects of d-amphetamine on startle reactivity and brain monoamines. Neuropsychopharmacology (2004) 29:1282–93. doi:10.1038/sj.npp.1300428
45. Dunn HA, Ferguson SS. PDZ protein regulation of G protein-coupled receptor trafficking and signaling pathways. Mol Pharmacol (2015) 88:624–39. doi:10.1124/mol.115.098509
46. Cottingham C, Wang Q. α2 Adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy. Neurosci Biobehav Rev (2012) 36:2214–25. doi:10.1016/j.neubiorev.2012.07.011
47. Arnsten AFT. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother (2010) 10:1595–605. doi:10.1586/ern.10.133
48. Dinan TG, Cryan JF. The impact of gut microbiota on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care (2015) 18:552–8. doi:10.1097/MCO.0000000000000221
49. Katzung BG. Introduction to autonomic pharmacology. In: Katzung BG, Trevor AJ, editors. Basic and Clinical Pharmacology. New York: McGraw-Hill Education (2015). p. 87–194.
50. Starke K. Presynaptic autoreceptors in the third decade: focus on α2-adrenoceptors. J Neurochem (2001) 78:685–93. doi:10.1046/j.1471-4159.2001.00484.x
51. MacDonald E, Kobilka BK, Scheinin M. Gene targeting – homing in on α2-adrenoceptor-subtype function. Trends Pharmacol Sci (1997) 18:211–9. doi:10.1016/S0165-6147(97)90625-8
52. Gilsbach R, Hein L. Are the pharmacology and physiology of α2adrenoceptors determined by α2-heteroreceptors and autoreceptors respectively? Br J Pharmacol (2012) 165:90–102. doi:10.1111/j.1476-5381.2011.01533.x
53. Trendelenburg AU, Klebroff W, Hein L, Starke K. A study of presynaptic α2-autoreceptors in α2A/D-, α2B- and α2C-adrenoceptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 364:117–30. doi:10.1007/ s002100100423
54. Scheibner J, Trendelenburg AU, Hein L, Starke K. Stimulation frequencynoradrenaline release relationships examined in α2A-,α2B- and α2C-adrenoceptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 364:321–8. doi:10.1007/s002100100432
55. Fagerholm V, Rokka J, Nyman L, Sallinen J, Tiihonen J, Tupala E, et al. Autoradiographic characterization of α2C-adrenoceptors in the human striatum. Synapse (2008) 62:508–15. doi:10.1002/syn.20520
56. Finnema SJ, Hughes ZA, Haaparanta-Solin M, Stepanov V, Nakao R, Varnäs K, et al. Amphetamine decreases α(2C)-adrenoceptor binding of [(11)C]ORM-13070: a PET study in the primate brain. Int J Neuropsychopharmacol (2015) 18:yu081. doi:10.1093/ijnp/pyu081
57. Uhlen S, Muceniece R, Rangel N, Tiger G, Wikberg JE. Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacol Toxicol (1995) 76:353–64. doi:10.1111/j.1600-0773.1995.tb00161.x
58. Uhlen S, Porter AC, Neubig RR. The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther (1994) 271:1558–65.
59. Holmberg M, Fagerholm V, Scheinin M. Regional distribution of α2C-adrenoceptors in brain and spinal cord of control mice and transgenic mice overexpressing the α2C-subtype: an autoradiographic study with [3H]RX821002 and [3H]rauwolscine. Neuroscience (2003) 117:875–98. doi:10.1016/S0306-4522(02)00966-1
60. Holmberg M, Scheinin M, Kurose H, Miettinen R. Adrenergic α(2C)-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience (1999) 93:1323–33. doi:10.1016/S0306-4522(99)00260-2
61. Winzer-Serhan UH, Raymon HK, Broide RS, Chen Y, Leslie FM. Expression of α2 adrenoceptors during rat brain development – II. α(2C) messenger RNA expression and [3H]rauwolscine binding. Neuroscience (1997) 76:261–72. doi:10.1016/S0306-4522(96)00369-7
62. Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, et al. Validation of [11C]ORM-13070 as a PET tracer for alpha2c-adrenocep-tors in the human brain. Synapse (2015) 69:172–81. doi:10.1002/syn.21798
63. Crassous PA, Cardinaletti C, Carrieri A, Bruni B, Di Vaira M, Gentili F, et al. α2-Adrenoreceptors profile modulation. 3.1 (R)-(+)-m-nitrobiphenyline, a new efficient and α2c-subtype selective agonist. J Med Chem (2007) 50:3964–8. doi:10.1021/jm061487a
64. Zhang W, Klimek V, Farley JT, Zhu MY, Ordway GA. α(2C) adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther (1999) 289:1286–92.
65. Zhang W, Ordway GA. The α2C-adrenoceptor modulates GABA release in mouse striatum. Mol Brain Res (2003) 112:24–32. doi:10.1016/ S0169-328X(03)00026-3
66. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. d-Amphetamine and l-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the α(2C)-adrenergic receptor subtype. Neuroscience (1998) 86:959–65. doi:10.1016/S0306-4522(98)00100-6
67. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, Sjöholm B, et al. Genetic alteration of α(2C)-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective α2-adrenoceptor agonist. Mol Pharmacol (1997) 51:36–46.
68. Brand SJ, Moller M, Harvey BH. A review of biomarkers in mood and psychotic disorders: a dissection of clinical vs. preclinical correlates. Curr Neuropharmacol (2015) 13:324–68. doi:10.2174/1570159X13666150307004545
69. Link R, Daunt D, Barsh G, Chruscinski A, Kobilka B. Cloning of two mouse genes encoding α2-adrenergic receptor subtypes and identification of a single amino acid in the mouse α2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol (1992) 42:16–27.
70. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem (1983) 41:1769–73. doi:10.1111/j.1471-4159.1983.tb00893.x
71. Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci (1989) 9:2051–65.
72. Kuczenski R, Segal DS. Regional norepinephrine response to amphetamine using dialysis: comparison with caudate dopamine. Synapse (1992) 11:164–9. doi:10.1002/syn.890110210
73. Ihalainen JA, Tanila H, Scheinin M, Riekkinen P Jr. α2C-Adrenoceptors modulate the effect of methylphenidate on response rate and discrimination accuracy in an operant test. Brain Res Bull (2001) 54:553–7. doi:10.1016/ S0361-9230(01)00449-X
74. Kawaguchi Y, Wilson CJ, Emson PC. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci (1990) 10:3421–38.
75. Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol (2009) 2:95–109. doi:10.2174/1874467210902010095
76. Reynolds GP. The neurochemistry of schizophrenia. Psychiatry (2008) 7:425–9. doi:10.1016/j.mppsy.2008.07.014
77. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol (2003) 70:83–244. doi:10.1016/S0301-0082(03)00087-X
78. Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol (2014) 29:503–16. doi:10.1002/ hup.2429
79. Timofeeva OA, Levin ED. Idazoxan blocks the nicotine-induced reversal of the memory impairment caused by the NMDA glutamate receptor antagonist dizocilpine. Pharmacol Biochem Behav (2008) 90:372–81. doi:10.1016/j.pbb.2008.03.011
80. Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, et al. The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology (2007) 33:1980–91. doi:10.1038/sj.npp.1301580
81. Jentsch JD, Anzivino LA. A low dose of the alpha2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats. Psychopharmacology (2004) 175:76–83. doi:10.1007/s00213-004-1772-3
82. Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD. Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology (2005) 30:1500–10. doi:10.1038/sj.npp.1300700
83. Jimenez-Rivera CA, Figueroa J, Vazquez-Torres R, Velez-Hernandez ME, Schwarz D, Velasquez-Martinez MC, et al. Presynaptic inhibition of glutamate transmission by alpha2 receptors in the VTA. Eur J Neurosci (2012) 35:1406–15. doi:10.1111/j.1460-9568.2012.08029.x
84. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH. Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol (2005) 8:315–27. doi:10.1017/S1461145705005328
85. Jardemark K, Marcus MM, Shahid M, Svensson TH. Effects of asenapine on prefrontal N-methyl-d-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse (2010) 64:870–4. doi:10.1002/ syn.20803
86. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol (2012) 3:195. doi:10.3389/ fphar.2012.00195
87. Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci (2013) 7:55. doi:10.3389/fncel.2013.00055
88. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) (2004) 174:45–53. doi:10.1007/s00213-004-1794-x
89. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 63:1121–9. doi:10.1001/archpsyc.63.10.1121
90. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry (2007) 61:1161–70. doi:10.1016/j.biopsych.2006.08.050
91. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 8:1703–18. doi:10.1586/14737175.8.11.1703
92. Raiteri M, Marchi M, Paudice P, Pittaluga A. Muscarinic receptors mediating inhibition of gamma-aminobutyric acid release in rat corpus striatum and their pharmacological characterization. J Pharmacol Exp Ther (1990) 254:496–501.
93. Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U S A (2001) 98:12320–2. doi:10.1073/pnas.231475998
94. Kharade SM, Gumate DS, Naikwade NS. A review: hypothesis of depression and role of antidepressant drugs. Int J Pharm Pharm Sci (2010) 2:3–6.
95. Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety (2014) 31:291–6. doi:10.1002/da.22227
96. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry (2002) 17:306–10. doi:10.1016/S0924-9338(02)00654-5
97. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature (2008) 455:894–902. doi:10.1038/nature07455
98. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry (2001) 178:234–41. doi:10.1192/bjp.178.3.234
99. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry (2006) 163:1905–17. doi:10.1176/ajp.2006.163.11.1905
100. De Paermentier F, Mauger JM, Lowther S, Crompton MR, Katona CLE, Horton RW. Brain α-adrenoceptors in depressed suicides. Brain Res (1997) 757:60–8. doi:10.1016/S0006-8993(97)00138-8
101. Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V. Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry (2003) 53:315–23. doi:10.1016/S0006-3223(02)01728-6
102. Ordway GA, Widdowson PS, Smith KS, Halaris A. Agonist binding to α2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem (1994) 63:617–24. doi:10.1046/j.1471-4159.1994.63020617.x
103. González AM, Pascual J, Meana JJ, Barturen F, Del Arco C, Pazos A, et al. Autoradiographic demonstration of increased α2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem (1994) 63:256–65. doi:10.1046/j.1471-4159.1994.63010256.x
104. Callado LF, Meana JJ, Grijalba B, Pazos A, Sastre M, García-Sevilla JA. Selective increase of α(2A)-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem (1998) 70:1114–23. doi:10.1046/j.1471-4159.1998.70031114.x
105. Javier Meana J, Barturen F, Garcia-Sevilla JA. α2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry (1992) 31:471–90. doi:10.1016/0006-3223(92)90259-3
106. Meana JJ, García-Sevilla JA. Increased α2;-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm (1987) 70:377–81. doi:10.1007/BF01253612
107. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol (2003) 13:57–66. doi:10.1016/S0924-977X(02)00173-6
108. Marshall RJ. The pharmacology of mianserin—an update. Br J Clin Pharmacol (1983) 15:263S–8S. doi:10.1111/j.1365-2125.1983.tb05874.x
109. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (2005) 177:245–55. doi:10.1007/s00213-004-2048-7
110. Castagné V, Moser P, Roux S, Porsolt RD. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci (2011) 55:1–14. doi:10.1002/0471142301.ns0810as55
111. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry (2004) 9:326–57. doi:10.1038/sj.mp.4001457
112. Holmes PV. Rodent models of depression: reexamining validity without anthropomorphic inference. Crit Rev Neurobiol (2003) 15:143–74. doi:10.1615/CritRevNeurobiol.v15.i2.30
113. Cottingham C, Li X, Wang Q. Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin. Neuropharmacology (2012) 62:2354–62. doi:10.1016/j.neuropharm.2012.02.011
114. Cervo L, Samanin R. Clonidine causes antidepressant-like effects in rats by activating α2-adrenoceptors outside the locus coeruleus. Eur J Pharmacol (1991) 193:309–13. doi:10.1016/0014-2999(91)90144-F
115. Stone EA, Lin Y, Sarfraz Y, Quartermain D. Antidepressant-like action of intracerebral 6-fluoronorepinephrine, a selective full α-adrenoceptor agonist. Int J Neuropsychopharmacol (2011) 14:319–31. doi:10.1017/ S1461145710000507
116. Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, et al. Addition of the α2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology (2004) 29:1166–71. doi:10.1038/sj.npp.1300418
117. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs (1996) 5:389–402. doi:10.2165/00023210-199605050-00007
118. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol (2009) 19:457–65. doi:10.1016/j.euroneuro.2009.01.015
119. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry (2010) 167:281–8. doi:10.1176/appi.ajp.2009.09020186
120. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol (2010) 6:285–312. doi:10.1146/annurev.clinpsy.121208.131305
121. Hammar Å, Årdal G. Cognitive functioning in major depression – a summary. Front Hum Neurosci (2009) 3:26. doi:10.3389/neuro.09.026.2009
122. Campbell S, MacQueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci (2004) 29:417–26.
123. Flugge G. Effects of cortisol on brain alpha2-adrenoceptors: potential role in stress. Neurosci Biobehav Rev (1999) 23:949–56. doi:10.1016/ S0149-7634(99)00028-7
124. Schule C, Baghai T, Zwanzger P, Rupprecht R. Attenuation of HPA axis hyperactivity and simultaneous clinical deterioration in a depressed patient treated with mirtazapine. World J Biol Psychiatry (2001) 2:103–5. doi:10.3109/15622970109027501
125. Schüle C, Baghai T, Zwanzger P, Ella R, Eser D, Padberg F, et al. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (2003) 166:271–5. doi:10.1007/ s00213-002-1356-z
126. Weber C-C, Eckert GP, Muller WE. Effects of antidepressants on the brain// plasma distribution of corticosterone. Neuropsychopharmacology (2006) 31:2443–8. doi:10.1038/sj.npp.1301076
127. Glue P, Wilson S, Campling GM, Knightly M, Franklin M, Cowen PJ, et al. Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology (1992) 17:261–6. doi:10.1016/0306-4530(92)90066-G
128. Price LH, Charney DS, Rubin AL, Heninger GR. Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine. Arch Gen Psychiatry (1986) 43:849–58. doi:10.1001/archpsyc.1986.01800090035006
129. Finn DP, Hudson AL, Kinoshita H, Coventry TL, Jessop DS, Nutt DJ, et al. Imidazoline2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic-pituitary-adrenal axis activity in control and acute restraint stressed rats. J Psychopharmacol (2004) 18:47–53. doi:10.1177/0269881104040231
130. Báez M, Volosin M. Corticosterone influences forced swim-induced immobility. Pharmacol Biochem Behav (1994) 49:729–36. doi:10.1016/0091-3057(94)90093-0
131. Korte SM, De Kloet ER, Buwalda B, Bouman SD, Bohus B. Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur J Pharmacol (1996) 301:19–25. doi:10.1016/0014-2999(96)00064-7
132. Lehto J, Scheinin A, Johansson J, Marjamäki P, Arponen E, Scheinin H, et al. Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070. Synapse (2016) 70:57–65. doi:10.1002/syn.21872
133. Lu L, Ordway GA. Alpha2C-adrenoceptors mediate inhibition of forskolinstimulated cAMP production in rat striatum. Brain Res Mol Brain Res (1997) 52:228–34. doi:10.1016/S0169-328X(97)00257-X
134. Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 65:585–96. doi:10.1016/j.neuron.2010.02.014
135. Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28:913–22. doi:10.1016/j.pnpbp.2004.05.033
136. Moller M, Swanepoel T, Harvey BH. Neurodevelopmental animal models reveal the convergent role of neurotransmitter systems, inflammation, and oxidative stress as biomarkers of schizophrenia: implications for novel drug development. ACS Chem Neurosci (2015) 6:987–1016. doi:10.1021/ cn5003368
137. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull (2009) 35:549–62. doi:10.1093/schbul/sbp006
138. Grunder G, Hippius H, Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov (2009) 8:197–202. doi:10.1038/nrd2806
139. Svensson TH. α-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry (2003) 27:1145–58. doi:10.1016/j.pnpbp.2003.09.009
140. Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science (1999) 286:105–7. doi:10.1126/science.286.5437.105
141. Farde L, Wiesel FA, Nordström AL, Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (1989) 99:S28–31. doi:10.1007/BF00442555
142. Farde L, Nordström AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl (1992) 17:30–3.
143. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia human and animal model studies. Arch Gen Psychiatry (1990) 47:181–8. doi:10.1001/archpsyc.1990.01810140081011
144. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull (1987) 13:643–68. doi:10.1093/schbul/13.4.643
145. Flaten MA. Test-retest reliability of the somatosensory blink reflex and its inhibition. Int J Psychophysiol (2002) 45:261–5. doi:10.1016/ S0167-8760(02)00034-X
146. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull (1990) 25:485–98. doi:10.1016/0361-9230(90)90241-Q
147. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry (1993) 34:361–72. doi:10.1016/0006-3223(93)90180-L
148. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther (1994) 271:787–94.
149. Varty GB, Higgins GA, Higgins GA. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (1995) 122:15–26. doi:10.1007/ BF02246437
150. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry (2002) 7:1039–53. doi:10.1038/sj.mp.4001159
151. Depoortere R, Perrault G, Sanger DJ. Potentiation of prepulse inhibition of the startle reflex in rats: pharmacological evaluation of the procedure as a model for detecting antipsychotic activity. Psychopharmacology (1997) 132:366–74. doi:10.1007/s002130050357
152. Swerdlow NR, Talledo J, Sutherland AN, Nagy D, Shoemaker JM. Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology (2006) 31:2011–21. doi:10.1038/sj.npp.1301043
153. During S, Glenthoj BY, Andersen GS, Oranje B. Effects of dopamine D2/ D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology (2014) 39:3000–8. doi:10.1038/npp.2014.152
154. Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry (2006) 60:597–603. doi:10.1016/j.biopsych. 2006.03.058
155. Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry. Neuropsychopharmacology (2014) 39:2485–96. doi:10.1038/npp.2014.102
156. Larrauri JA, Levin ED. The alpha(2)-adrenergic antagonist idazoxan counteracts prepulse inhibition deficits caused by amphetamine or dizocilpine in rats. Psychopharmacology (Berl) (2012) 219:99–108. doi:10.1007/ s00213-011-2377-2
157. Ozcetin A, Cevreli B, Uzbay T. Investigation of the role of alpha-2 adrenergic receptors on prepulse inhibition of acoustic startle reflex in rats. Synapse (2016) 70(12):501–7. doi:10.1002/syn.21923
158. Powell SB, Palomo J, Carasso BS, Bakshi VP, Geyer MA. Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Psychopharmacology (Berl) (2005) 180:491–500. doi:10.1007/ s00213-005-2193-7
159. Jones C, Watson D, Fone K. Animal models of schizophrenia. Br J Pharmacol (2011) 164:1162–94. doi:10.1111/j.1476-5381.2011.01386.x
160. Fone KC, Porkess MV. Behavioural and neurochemical effects of postweaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev (2008) 32:1087–102. doi:10.1016/j.neubiorev.2008.03.003
161. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol (2000) 14:1–21. doi:10.1615/CritRevNeurobiol.v14.i1.10
162. Trivedi JK. Cognitive deficits in psychiatric disorders: current status. Indian J Psychiatry (2006) 48:10–20. doi:10.4103/0019-5545.31613
163. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat (2006) 2:531–6. doi:10.2147/ nedt.2006.2.4.531
164. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol (2012) 213:11–37. doi:10.1007/978-3-642-25758-2_2
165. Kahn RS, Keefe RSE. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry (2013) 70:1107–12. doi:10.1001/jamapsychiatry.2013.155
166. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl) (1996) 124:126–33. doi:10.1007/ BF02245612
167. Didriksen M, Skarsfeldt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) (2007) 193:225–33. doi:10.1007/ s00213-007-0774-3
168. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res (2007) 184:31–8. doi:10.1016/j.bbr.2007.06.012
169. Wolff MC, Leander JD. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology (Berl) (2003) 168:410–6. doi:10.1007/s00213-003-1449-3
170. Amitai N, Markou A. Disruption of performance in the 5-choice serial reaction time task induced by administration of NMDA receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 68:5–16. doi:10.1016/j.biopsych.2010.03.004
171. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev (2008) 32:1014–23. doi:10.1016/j.neubiorev.2008.03.012
172. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res (2008) 186:197–207. doi:10.1016/j.bbr.2007.08.012
173. Terry AV, Hill WD, Parikh V, Waller JL, Evans DR, Mahadik SP. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology (2003) 28:300–9. doi:10.1038/sj.npp.1300039
174. Favalli G, Li J, Belmonte-de-Abreu P, Wong AHC, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res (2012) 46:1–11. doi:10.1016/j.jpsychires.2011.09.022
175. Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry (2013) 4:45. doi:10.3389/fpsyt.2013.00045
176. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull (2006) 32:S44–63. doi:10.1093/schbul/sbl029
177. Wilson CA, Koenig JI. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2014) 24:759–73. doi:10.1016/j.euroneuro.2013.11.008
178. Möller M, Du Preez JL, Emsley R, Harvey BH. Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. Eur Neuropsychopharmacol (2011) 21:471–83. doi:10.1016/j.euroneuro.2010.09.006
179. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther (2010) 334:171–81. doi:10.1124/jpet.110.167346
180. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res (2008) 100:39–52. doi:10.1016/j.schres.2007.11.034
181. Arnsten A, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci (1988) 8:4287–98.
182. Franowicz JS, Arnsten AF. Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys. Neuropsychopharmacology (1999) 21:611–21. doi:10.1016/S0893-133X(99)00060-3
183. Cai JX, Ma YY, Xu L, Hu XT. Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine. Brain Res (1993) 614:191–6. doi:10.1016/0006-8993(93)91034-P
184. Jäkälä P, Riekkinen M, Sirviö J, Koivisto E, Kejonen K, Vanhanen M, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology (1999) 20:460–70. doi:10.1016/S0893-133X(98)00127-4
185. Arnsten A, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science (1985) 230:1273–6. doi:10.1126/science.2999977
186. Lakhlani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, Maze M, et al. Substitution of a mutant alpha2a-adrenergic receptor via “hit and run” gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci U S A (1997) 94:9950–5. doi:10.1073/pnas.94.18.9950
187. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc (2006) 1:848–58. doi:10.1038/nprot.2006.116
188. Marston H, Everitt B, Robbins T. Comparative effects of excitotoxic lesions of the hippocampus and septum/diagonal band on conditional visual discrimination and spatial learning. Neuropsychologia (1993) 31:1099–118. doi:10.1016/0028-3932(93)90035-X
189. Annett L, McGregor A, Robbins T. The effects of ibotenic acid lesions of the nucleus accumbens on spatial learning and extinction in the rat. Behav Brain Res (1989) 31:231–42. doi:10.1016/0166-4328(89)90005-3
190. Floresco SB, Seamans JK, Phillips AG. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J Neurosci (1997) 17:1880–90.
191. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res (1988) 31:47–59. doi:10.1016/0166-4328(88)90157-X
192. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process (2012) 13:93–110. doi:10.1007/s10339-011-0430-z
193. Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem (2010) 17:794–800. doi:10.1101/ lm.1650110
194. Cohen SJ, Stackman RW Jr. Assessing rodent hippocampal involvement in the novel object recognition task. a review. Behav Brain Res (2015) 285:105–17. doi:10.1016/j.bbr.2014.08.002
195. Reger ML, Hovda DA, Giza CC. Ontogeny of rat recognition memory measured by the novel object recognition task. Dev Psychobiol (2009) 51:672–8. doi:10.1002/dev.20402
196. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol (2014) 220:223–50. doi:10.1007/978-3-642-45106-5_9
197. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev (2012) 64:238–58. doi:10.1124/pr.111.005108
198. Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol (2011) 9:530–52. doi:10.2174/ 157015911798376262
199. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci (1995) 15:7539–47.
200. Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, et al. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-d-aspartate receptor activity. J Neurosci Res (2003) 72:622–8. doi:10.1002/jnr.10609
201. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res (2006) 82:95–106. doi:10.1016/j.schres.2005.11.021
202. Mannari C, Origlia N, Scatena A, Del Debbio A, Catena M, Dell'Agnello G, et al. BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake. Cell Mol Neurobiol (2008) 28:457–68. doi:10.1007/ s10571-007-9254-x
203. Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett (2011) 491:207–10. doi:10.1016/j.neulet.2011.01.039
204. Rizk P, Salazar J, Raisman-Vozari R, Marien M, Ruberg M, Colpaert F, et al. The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology (2005) 31:1146–57. doi:10.1038/sj.npp.1300954
205. Yanpallewar S, Fernandes K, Marathe S, Vadodaria K, Jhaveri D, Rommelfanger K, et al. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci (2010) 30:1096–109. doi:10.1523/JNEUROSCI.2309-09.2010
206. Francis BM, Yang J, Hajderi E, Brown ME, Michalski B, McLaurin J, et al. Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. Neuropsychopharmacology (2012) 37:1934–44. doi:10.1038/npp.2012.40
207. Kuppers E, Beyer C. Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells. Neuroreport (2001) 12:1175–9. doi:10.1097/00001756-200105080-00025
208. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology (2007) 33:73–83. doi:10.1038/sj.npp.1301571
209. Marmigere F, Rage F, Tapia-Arancibia L. GABA-glutamate interaction in the control of BDNF expression in hypothalamic neurons. Neurochem Int (2003) 42:353–8. doi:10.1016/S0197-0186(02)00100-6
210. West AE, Griffith EC, Greenberg ME. Regulation of transcription factors by neuronal activity. Nat Rev Neurosci (2002) 3:921–31. doi:10.1038/ nrn987
211. Tuvikene J, Pruunsild P, Orav E, Esvald EE, Timmusk T. AP-1 transcription factors mediate BDNF-positive feedback loop in cortical neurons. J Neurosci (2016) 36:1290–305. doi:10.1523/JNEUROSCI.3360-15.2016
212. Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev (2009) 89:121–45. doi:10.1152/physrev.00017.2008
213. Radwanska K, Schenatto-Pereira G, Ziółkowska M, Łukasiewicz K, Giese KP. Mapping fear memory consolidation and extinction-specific expression of JunB. Neurobiol Learn Mem (2015) 125:106–12. doi:10.1016/j.nlm.2015.08.007
214. Hsieh TF, Simler S, Vergnes M, Gass P, Marescaux C, Wiegand SJ, et al. BDNF restores the expression of Jun and Fos inducible transcription factors in the rat brain following repetitive electroconvulsive seizures. Exp Neurol (1998) 149:161–74. doi:10.1006/exnr.1997.6686
215. Tomasetti C, Iasevoli F, Buonaguro EF, De Berardis D, Fornaro M, Fiengo ALC, et al. Treating the synapse in major psychiatric disorders: the role of post-synaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions. Int J Mol Sci (2017) 18:135. doi:10.3390/ ijms18010135
216. Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors. J Biol Chem (2003) 278:32405–12. doi:10.1074/jbc.M304195200
217. Lu R, Chen Y, Cottingham C, Peng N, Jiao K, Limbird LE, et al. Enhanced hypotensive, bradycardic, and hypnotic responses to α(2)-adrenergic agonists in spinophilin-null mice are accompanied by increased G protein coupling to the α(2A)-adrenergic receptor. Mol Pharmacol (2010) 78:279–86. doi:10.1124/mol.110.065300
218. Wang X, Zeng W, Soyombo AA, Tang W, Ross EM, Barnes AP, et al. Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol (2005) 7:405–11. doi:10.1038/ncb1237
219. Grabrucker S, Proepper C, Mangus K, Eckert M, Chhabra R, Schmeisser MJ, et al. The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation. Exp Neurol (2014) 253:126–37. doi:10.1016/j.expneurol.2013.12.015
220. Qiao H, Li MX, Xu C, Chen HB, An SC, Ma XM. Dendritic spines in depression: what we learned from animal models. Neural Plast (2016) 2016:8056370. doi:10.1155/2016/8056370
221. Dean B, Gibbons AS, Boer S, Uezato A, Meador-Woodruff J, Scarr E, et al. Changes in cortical N-methyl-d-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. Aust N Z J Psychiatry (2016) 50:275–83. doi:10.1177/0004867415586601
222. de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, et al. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. Eur Neuropsychopharmacol (2015) 25:566–82. doi:10.1016/j.euroneuro.2015.01.003
223. de Bartolomeis A, Marmo F, Buonaguro EF, Latte G, Tomasetti C, Iasevoli F. Switching antipsychotics: imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naive vs. antipsychoticexposed rats. Prog Neuropsychopharmacol Biol Psychiatry (2016) 70:24–38. doi:10.1016/j.pnpbp.2016.04.015
224. Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl) (2010) 212:329–44. doi:10.1007/s00213-010-1954-0
225. Luoni A, Macchi F, Papp M, Molteni R, Riva MA. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int J Neuropsychopharmacol (2015) 18(4):pyu061. doi:10.1093/ijnp/pyu061
226. O'Leary OF, Wu X, Castren E. Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling. Psychoneuroendocrinology (2009) 34:367–81. doi:10.1016/j.psyneuen.2008.09.015
227. Peykov S, Berkel S, Schoen M, Weiss K, Degenhardt F, Strohmaier J, et al. Identification and functional characterization of rare SHANK2 variants in schizophrenia. Mol Psychiatry (2015) 20:1489–98. doi:10.1038/mp.2014.172
228. Zhang W, Wu J, Ward MD, Yang S, Chuang YA, Xiao M, et al. Structural basis of arc binding to synaptic proteins: implications for cognitive disease. Neuron (2015) 86:490–500. doi:10.1016/j.neuron.2015.03.030
229. Stan TL, Sousa VC, Zhang X, Ono M, Svenningsson P. Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain. Eur Neuropsychopharmacol (2015) 25:1714–22. doi:10.1016/j.euroneuro.2015.07.007
230. Dell'aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res Bull (2009) 79:123–9. doi:10.1016/j.brainresbull.2009.01.006
231. de Bartolomeis A, Avvisati L, Iasevoli F, Tomasetti C. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. Eur J Pharmacol (2013) 718:502–23. doi:10.1016/j.ejphar.2013.06.034
232. Wadenberg ML, Wiker C, Svensson TH. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol (2007) 10:191–202. doi:10.1017/S1461145706006638
233. Wilson MC. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev (2000) 24:51–7. doi:10.1016/S0149-7634(99)00064-0
234. Bruno KJ, Hess EJ. The α2C-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis (2006) 23:679–88. doi:10.1016/j.nbd.2006.05.007
235. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry (2004) 161:1537–47. doi:10.1176/appi.ajp.161.9.1537
236. Palazidou E. Quetiapine: a new option in bipolar depression. Future Prescr (2009) 10:9–14. doi:10.1002/fps.56
237. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs (2012) 26:435–60. doi:10.2165/11203840-000000000-00000
238. Garner M, Mohler H, Stein DJ, Mueggler T, Baldwin DS. Research in anxiety disorders: from the bench to the bedside. Eur Neuropsychopharmacol (2009) 19:381–90. doi:10.1016/j.euroneuro.2009.01.011
239. Brand SJ, Harvey BH. Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression I: bio-behavioural validation and response to imipramine. Acta Neuropsychiatr (2017) 29:193–206. doi:10.1017/neu.2016.44
240. Brand SJ, Harvey BH. Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. Acta Neuropsychiatr (2017) 29:207–21. doi:10.1017/neu.2016.50
241. El-Hage W, Leman S, Camus V, Belzung C. Mechanisms of antidepressant resistance. Front Pharmacol (2013) 4:146. doi:10.3389/fphar. 2013.00146
242. Millan MJ, Goodwin GM, Meyer-Lindenberg A, Ove Ogren S. Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur Neuropsychopharmacol (2015) 25:599–656. doi:10.1016/j.euroneuro.2015.01.016
243. Cleary L, Murad K, Bexis S, Docherty JR. The α1D-adrenoceptor antagonist BMY 7378 is also an α2C-adrenoceptor antagonist. Auton Autacoid Pharmacol (2005) 25:135–41. doi:10.1111/j.1474-8673.2005.00342.x
244. Patel SD, Habeski WM, Min H, Zhang J, Roof R, Snyder B, et al. Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4] diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective α2C adrenergic receptor antagonist. Bioorg Med Chem Lett (2008) 18:5689–93. doi:10.1016/j.bmcl.2008.08.055
245. Corboz MR, Rivelli MA, McCormick KD, Wan Y, Shah H, Umland S, et al. Pharmacological characterization of a novel alpha2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A). J Pharmacol Exp Ther (2011) 337:256–66. doi:10.1124/jpet.110.175794
246. Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, et al. 11C-ORM-13070, a novel PET ligand for brain alpha2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging (2014) 41:1947–56. doi:10.1007/s00259-014-2782-y
247. Corboz MR, Rivelli MA, Shah H, Boyce CW, McCormick KD, Chapman RW, et al. Role of α2-adrenoceptors in electrical field stimulation-induced contraction of pig nasal mucosa and pharmacologic characterization of a novel α2C-adrenoceptor agonist. Am J Rhinol Allergy (2013) 27:84–90. doi:10.2500/ajra.2013.27.3842
248. Dooley K, Zon LI. Zebrafish: a model system for the study of human disease. Curr Opin Genet Dev (2000) 10:252–6. doi:10.1016/S0959-437X(00)00074-5
249. Ruuskanen JO, Peitsaro N, Kaslin JV, Panula P, Scheinin M. Expression and function of alpha-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions. J Neurochem (2005) 94:1559–69. doi:10.1111/j.1471-4159.2005.03305.x
250. Ruuskanen JO, Laurila J, Xhaard H, Rantanen V-V, Vuoriluoto K, Wurster S, et al. Conserved structural, pharmacological and functional properties among the three human and five zebrafish α(2)-adrenoceptors. Br J Pharmacol (2005) 144:165–77. doi:10.1038/sj.bjp.0706057